Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib with chemo and avelumab in urothelial carcinoma
NCT04887831Phase 2Terminated
- Sponsor
- G1 Therapeutics, Inc.
- Start
- Jun 2021
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial in urothelial carcinoma (UC) comparing Standard of Care with Trilaciclib Arm (2 arms). Primary endpoint: Progression-Free Survival up to 96 weeks. Started Jun 2021; status: terminated.
02
Drugs
trilaciclib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04887831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04887831.